March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.
FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.
A study published in the American Heart Association's journal Circulation explored whether babies born with a congenital heart defects and their mothers may experience an elevated risk of cancer.